Organochlorides

Daré Bioscience to Present at the 2021 Controlled Release Society Virtual Annual Meeting to be held July 25-29, 2021

Retrieved on: 
Monday, July 26, 2021

SAN DIEGO, July 26, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that David Friend, PhD, the company’s Chief Scientific Officer, will present data from preclinical and clinical studies related to DARE-BV1 at the 2021 Controlled Release Society (CRS) Virtual Annual Meeting on July 27th. Daré submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for DARE-BV1 for the treatment of bacterial vaginosis in June of 2021.

Key Points: 
  • DARE-BV1 is an investigational thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% designed as a one-time vaginally-administered treatment for bacterial vaginosis.
  • Find out more information about the 2021 CRS Virtual Annual Meeting by visiting the CRS website: https://www.controlledreleasesociety.org/events/2021-crs-virtual-annual-... .
  • Dr. Friends presentation will be available following the conclusion of the 2021 CRS Virtual Annual Meeting under Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com .
  • Dar cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements.

Trial Launches to Evaluate GlycoMimetics’ Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients

Retrieved on: 
Thursday, July 22, 2021

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians have treated the first patient in a Phase 1b/2 study evaluating the companys lead drug candidate, uproleselan, added to cladribine plus low dose cytarabine (LDAC) in patients with treated secondary AML (ts-AML).

Key Points: 
  • GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians have treated the first patient in a Phase 1b/2 study evaluating the companys lead drug candidate, uproleselan, added to cladribine plus low dose cytarabine (LDAC) in patients with treated secondary AML (ts-AML).
  • According to Eric Feldman, M.D., GlycoMimetics Chief Medical Officer, Patients with treated secondary AML have an extremely poor prognosis.
  • Our previous preclinical and clinical research supports the potential for these patients to benefit from the addition of uproleselan.
  • The Phase 1b/2 single-arm trial is enrolling patients 18 years or older, with a diagnosis of ts-AML who have not received therapy for their AML.

2021 Update Bulletin on Multiple Sclerosis - Ocrevus Has Been Approved by the European Commission - ResearchAndMarkets.com

Retrieved on: 
Friday, July 16, 2021

The "Multiple Sclerosis: Update Bulletin" newsletter has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Multiple Sclerosis: Update Bulletin" newsletter has been added to ResearchAndMarkets.com's offering.
  • This report presents key opinion leader (KOL) views on recent developments in the multiple sclerosis (MS) market.
  • Which agents are anticipated to lose market share as a result of Ocrevus' launch?
  • How do KOLs view Mavenclad, and how successful has the European launch been?

Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021

Retrieved on: 
Wednesday, May 19, 2021

b'+Number of patients with AE occurring from the start of study drug up to subsequent anti-cancer therapy.

Key Points: 
  • b'+Number of patients with AE occurring from the start of study drug up to subsequent anti-cancer therapy.
  • One previously disclosed event was attributed to progressive myeloma and lymphodepletion with cyclophosphamide and ALLO-647.
  • ET and can be accessed via the Company\'s website at www.allogene.com under the Investors tab in the News and Events section or by clicking the following link directly.
  • Any forward-looking statements that are made in this press release speak only as of the date of this press release.

Daré Bioscience Announces the Presentation of DARE-BVFREE Phase 3 Clinical Trial Results at the 2021 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists

Retrieved on: 
Monday, April 26, 2021

DARE-BV1 is an investigational thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% designed as a one-time vaginally-administered treatment for bacterial vaginosis.

Key Points: 
  • DARE-BV1 is an investigational thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% designed as a one-time vaginally-administered treatment for bacterial vaginosis.
  • Patients were evaluated during three clinic visits: Day 1 (screening and randomization visit), Day 7-14 (assessment visit), and Day 21-30 (test-of-cure visit).
  • \xe2\x80\x9cIn the DARE-BVFREE trial, DARE-BV1 was well-tolerated and demonstrated clinical cure efficacy rates superior to those shown by current branded prescription products for treatment of bacterial vaginosis.
  • You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made.

EMD Serono Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD® Use During the COVID-19 Pandemic

Retrieved on: 
Friday, April 23, 2021

The safety database analysis included cases of confirmed (n=160) or suspected (n=101) COVID-19 in MAVENCLAD-treated patients.

Key Points: 
  • The safety database analysis included cases of confirmed (n=160) or suspected (n=101) COVID-19 in MAVENCLAD-treated patients.
  • Based on the analysis, the majority of patients had mild to moderate respiratory symptoms and none required mechanical ventilation.
  • After the completion of 2 treatment courses, do not administer additional MAVENCLAD treatment during the next 2 years.
  • Women who become pregnant during treatment with MAVENCLAD should discontinue treatment.\nLymphopenia: MAVENCLAD causes a dose-dependent reduction in lymphocyte count.

Merck Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD® Use During the COVID-19 Pandemic

Retrieved on: 
Friday, April 23, 2021

These findings appeared unique to MAVENCLAD across other high-efficacy MS therapies.

Key Points: 
  • These findings appeared unique to MAVENCLAD across other high-efficacy MS therapies.
  • The safety database analysis included cases of confirmed (n=160) or suspected (n=101) COVID-19 in MAVENCLAD-treated patients.
  • Based on the analysis, the majority of patients had mild to moderate respiratory symptoms and none required mechanical ventilation.
  • Merck holds the global rights to the Merck name and brand.

Daré Bioscience Reports Full Year 2020 Financial Results and Provides a Company Update

Retrieved on: 
Tuesday, March 30, 2021

Despite the unique challenges posed during 2020, we achieved two important corporate firsts in 2020.

Key Points: 
  • Despite the unique challenges posed during 2020, we achieved two important corporate firsts in 2020.
  • Dar solution: Novel, investigational thermosetting bioadhesive hydrogel formulated with clindamycin phosphate 2% as a first-line, single-administration treatment for bacterial vaginosis.
  • Dar will host a conference call and live webcast today at4:30 p.m. Eastern Timeto review the company's financial results for the year ended December 31, 2020 and to provide a company update.
  • Dar Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for womens health.

Kala Pharmaceuticals Announces Preferred Position for EYSUVIS™ on Cigna

Retrieved on: 
Tuesday, March 16, 2021

We are pleased to announce the addition of EYSUVIS to Cignas preferred formulary, reflecting a significant expansion of our commercial coverage and important progress toward our goal of securing broad patient access, said Todd Bazemore, Chief Operating Officer of Kala Pharmaceuticals.

Key Points: 
  • We are pleased to announce the addition of EYSUVIS to Cignas preferred formulary, reflecting a significant expansion of our commercial coverage and important progress toward our goal of securing broad patient access, said Todd Bazemore, Chief Operating Officer of Kala Pharmaceuticals.
  • EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% is approved for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.
  • EYSUVIS utilizes Kala's proprietary AMPPLIFY mucus-penetrating particle (MPP) Drug Delivery Technology to enhance penetration of loteprednol etabonate (LE) into target tissue of the ocular surface.
  • Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye.

Study Published in the European Journal of Oral Sciences Features AFYX Therapeutics’ Rivelin-CLO Patch for the Treatment of Oral Lichen Planus

Retrieved on: 
Thursday, March 11, 2021

This is the first study to show the successful transmucosal delivery of a corticosteroid using electrospun patch technology and confirmed that the drug delivered retained its anti-inflammatory activity.

Key Points: 
  • This is the first study to show the successful transmucosal delivery of a corticosteroid using electrospun patch technology and confirmed that the drug delivered retained its anti-inflammatory activity.
  • Rivelin-CLO is the first biodegradable oral adhesive patch designed for local delivery of clobetasol to treat symptomatic Oral Lichen Planus (OLP) lesions.
  • This new mucoadhesive patch technology holds great promise for the treatment of patients with mucosal diseases.
  • Rivelin is a muco-adhesive two layered patch that delivers a pharmaceutical product (such as clobetasol) directly to wet tissue surfaces.